Instrument Inactif

Communiqués Sagent Pharmaceuticals Inc

Actions

US7866921031

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

Communiqués

29/08/16	Nichi-Iko Pharmaceutical Co., Ltd. : Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.	BU
17/08/16	Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter	GL
09/08/16	Nichi-Iko Pharmaceutical Co., Ltd. : Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.	BU
01/08/16	Sagent Pharmaceuticals : Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of $21.75 Net Per Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals, Inc.	BU
22/07/16	The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.	BU
19/07/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	BU
18/07/16	Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Sagent Pharmaceuticals, Inc. to Nichi-Iko Pharmaceutical Co., Ltd. for $21.75 Per Share is Fair to Shareholders	BU
12/07/16	Sagent Pharmaceuticals : Acquisition May Not Be in the Best Interests of SGNT Shareholders	PR
12/07/16	Levi & Korsinsky, LLP Announces an Investigation Into the Sale of Sagent Pharmaceuticals, Inc. to Nichi-Iko Pharmaceutical Co., Ltd. for $21.75 Per Share is Fair to Shareholders -- SGNT	BU
12/07/16	Ryan & Maniskas, LLP : Announces Investigation of Sagent Pharmaceuticals, Inc.	PR
12/07/16	Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
11/07/16	SAGENT PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
11/07/16	SAGENT(SGNT) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Sagent Pharmaceuticals, Inc.; Are Shareholders Getting a Fair Price?	PR
11/07/16	Nichi-Iko Pharmaceutical Co., Ltd : to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction	BU
16/06/16	Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.	GL
03/05/16	Sagent Pharmaceuticals : Sets Date and Time for Release of First Quarter 2016 Financial Results	PU
03/05/16	Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results	GL
25/04/16	Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results	GL
23/03/16	Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development	GL
01/03/16	Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity Result Detected During Routine Quality Testing of Stability Samples at the 18-Month Interval	GL
25/02/16	Sagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations	GL
16/02/16	Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results	GL
03/02/16	Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results	GL
12/01/16	Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO® (Lidocaine HCl Jelly USP, 2%)	GL
08/01/16	Sagent Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference	GL